Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers

被引：33
|
作者：
Rexer, Brent N.
Ghosh, Ritwik
Arteaga, Carlos L. [1 ]
机构：
[1] Vanderbilt Univ, Sch Med, Div Oncol, Dept Med, Nashville, TN 37232 USA
来源：
CLINICAL CANCER RESEARCH | 2009年 / 15卷 / 14期
关键词：
CANCER; MTOR; ACTIVATION;
D O I：
10.1158/1078-0432.CCR-09-0872
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A small molecule inhibitor of MAP/ERK kinase (MEK) was effective against human breast cancer cells with a basal-like gene expression signature. Antitumor activity was limited by both feedback upregulation of phosphatidylinositol-3 kinase (PI3K)/AKT upon inhibition of MEK as well as loss of the phosphatase PTEN. Therefore, MEK inhibitors should preferably be investigated in combination with PI3K inhibitors in basal-like breast cancers. (Clin Cancer Res 2009;15(14) July 2009).
引用
收藏
页码：4518 / 4520
页数：3
相关论文
共 50 条
  • [1] PI3Kβ inhibition: all that glitters is not gold
    Torti, Mauro
    BLOOD, 2015, 125 (05) : 750 - 751
  • [2] PI3K and MEK Inhibition in Hypodiploid Acute Lymphoblastic Leukemia
    Comeaux, Evan
    Lin, Wenwei
    Chen, Taosheng
    Freeman, Burgess, III
    Mullighan, Charles G.
    BLOOD, 2016, 128 (22)
  • [3] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
    Britten, Carolyn D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (06) : 1395 - 1409
  • [4] PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
    Carolyn D. Britten
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1395 - 1409
  • [5] The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
    E J Haagensen
    S Kyle
    G S Beale
    R J Maxwell
    D R Newell
    British Journal of Cancer, 2012, 106 : 1386 - 1394
  • [6] MEK and PI3K inhibition in solid tumors: rationale and evidence to date
    Jokinen, E.
    Koivunen, J. P.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2015, 7 (03) : 170 - 180
  • [7] Combined MEK and PI3K Inhibition in a Mouse Model of Pancreatic Cancer
    Alagesan, Brinda
    Contino, Gianmarco
    Guimaraes, Alexander R.
    Corcoran, Ryan B.
    Deshpande, Vikram
    Wojtkiewicz, Gregory R.
    Hezel, Aram F.
    Wong, Kwok-Kin
    Loda, Massimo
    Weissleder, Ralph
    Benes, Cyril
    Engelman, Jeffrey A.
    Bardeesy, Nabeel
    CLINICAL CANCER RESEARCH, 2015, 21 (02) : 396 - 404
  • [8] The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
    Haagensen, E. J.
    Kyle, S.
    Beale, G. S.
    Maxwell, R. J.
    Newell, D. R.
    BRITISH JOURNAL OF CANCER, 2012, 106 (08) : 1386 - 1394
  • [9] Dual inhibition of MEK/MAPK and PI3K/Akt in multiple myeloma
    Steinbrunn, T.
    Stuehmer, T.
    Sayehli, C.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    ONKOLOGIE, 2012, 35 : 140 - 140
  • [10] Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
    Elina Jokinen
    Niina Laurila
    Jussi P Koivunen
    BMC Cancer, 12
12345